Company news
Marvel Biosciences Corp news in 2022
Marvel Biosciences Corp's news releases, calls and decks from 2022, newest first.
Marvel Biosciences Announces Letter Agreement for Market Stabilization and Liquidity Services
December 23, 2022
Marvel Biosciences Announces Stock Option Grant
December 20, 2022
Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
December 12, 2022
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression
December 7, 2022
Marvel Biosciences Announces Director Appointment and Resignation
November 24, 2022
Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum
November 22, 2022
Marvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies
November 14, 2022
Marvel Biosciences' Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer's Disease and Depression
November 7, 2022
Marvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer's Further Advancing Towards FDA Phase I Human Trials
November 1, 2022
Marvel Biosciences Advances Closer to Human Trials After the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
October 25, 2022
Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
October 17, 2022
Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression
October 4, 2022
Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer's Disease
August 31, 2022
Marvel Biosciences Closes Second Tranche of Private Placement
August 9, 2022
Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset
July 21, 2022
Marvel Biosciences Closes First Tranche of Private Placement
July 18, 2022
Marvel Biosciences Announces Non-Brokered Private Placement
June 21, 2022
Marvel Biosciences Initiates Formulation Development with Catalent
April 6, 2022
Marvel Biosciences Announces Second Quarter 2022 Financial Results
March 30, 2022
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
February 16, 2022
Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase
February 8, 2022
Marvel Biosciences Corp. Announces Change of Chief Financial Officer
February 1, 2022
Decks in 2022
- Investor Presentation (April 2022)
Investor deck · 31 slides · April 2022